The Potential — and Pitfalls — of Biosimilars

Guidehouse on Healthcare Podcast

With a global forecast of $30 billion by 2020, biosimilars of market-leading therapeutics are a reality. Why, then, would lower-cost medications mean lower provider profits? Here, we discuss how reimbursement is an obstacle to broad adoption.


Download the Full Transcript
Back to top